Immunology Investor Event
Expected advances in early Immunology Pipeline
6 Phase 1
readouts
3 Phase 1b (PoM)
readouts
8 Phase 2
readouts
H1 2022
-
TNFα inhibitor oral
H2 2022
-
anti-IL-13/TSLP NanobodyⓇ VHH:
Asthma
2022
-
Topical BTKI: AD
2023
eclitasertib (RIPK1): CLE
CD40L: SJS, SLE
rilzabrutinib (BTKI):
AD, CSU, Asthma
rilzabrutinib (oral BTKI): IgG4
-
-
-
H2 2022
anti-IL-13/OX40L NanobodyⓇ VHH
anti-TNFα/OX40L NanobodyⓇ VHH
IRAK-4 degrader oral
2023
non-beta IL-2
anti-TNFα/IL-23 NanobodyⓇ VHH
2023
TNFα inhibitor oral: Psoriasis
2024
anti-IL13/OX40L NanobodyⓇ VHH:
2024
AD
These products are currently under clinical investigation and their safety and efficacy have not been evaluated by any regulatory authority.
51 Immunology Investor Event
sanofiView entire presentation